Altiratinib

Drug Profile

Altiratinib

Alternative Names: DCC-22701; DCC-2701; DP-5164

Latest Information Update: 28 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Class Amides; Antineoplastics; Cyclopropanes; Dicarboxylic acids; Pyridines; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase inhibitors; Proto oncogene protein c met inhibitors; TIE 2 receptor antagonists; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Glioblastoma

Most Recent Events

  • 21 Mar 2016 Pharmacodynamics data from preclinical studies in Glioblastoma released by Deciphera Pharmaceuticals
  • 18 Aug 2015 Pharmacodynamics data from a preclinical study released by Deciphera
  • 22 Apr 2015 Pharmacodynamics data from preclinical studies in Solid tumours presented at the American Association for Cancer Research Annual Meeting (AACR-2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top